Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose safety, tolerability, pharmacokinetics and pharmacodynamics study of GSK189075 versus GW869682 in type 2 diabetes mellitus
2005-002978-30Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing GSK189075 arm, GW869682 arm and Placebo arm (3 arms). Primary endpoint: Safety and tolerability. Started Oct 2005; status: completed.
02
Drugs
remogliflozin etabonateSergliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-002978-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002978-30.